BACKGROUND: Albuminuria with normal serum creatinine occurs frequently in patients with sickle cell disease (SCD), but the rate of progression to more advanced chronic renal disease is unknown. The purpose of this study was to investigate the rate of progression of children and young adults with SCD and albuminuria over time. PROCEDURE: Urine albumin/creatinine (A/C) ratios and serum creatinine were obtained serially. Serum cystatin C levels were determined in a subgroup of 20 patients. RESULTS: Of 38 patients with SCD who had albuminuria (30 with microalbuminuria and 8 with proteinuria), 10.5% had progressive disease during follow-up of 20 +/- 12 months. Progressive disease was observed in 2 of 30 patients with MA because MA worsened to either intermittent proteinuria (1 patient), or persistent proteinuria after 7 months follow-up (1 patient). Two of eight patients with proteinuria worsened to nephrotic-range after 8 and 17 months with elevations of serum creatinine. All eight patients with proteinuria were treated with angiotensin blockade and/or hydroxyurea. Of those, six patients responded to treatment with decreased albuminuria and no changes in serum creatinine. Serum cystatin C level trended to increase before serum creatinine in patients with proteinuria. CONCLUSIONS: Patients with rapid progression to nephrotic-range proteinuria showed decreased kidney function. Therefore, patients with albuminuria should be monitored closely for progression, and therapy with hydroxyurea and/or angiotensin blockade should be considered for patients who develop proteinuria. Serum cystatin C appears more sensitive than serum creatinine to detect early decrease in kidney function. (c) 2007 Wiley-Liss, Inc.
BACKGROUND:Albuminuria with normal serum creatinine occurs frequently in patients with sickle cell disease (SCD), but the rate of progression to more advanced chronic renal disease is unknown. The purpose of this study was to investigate the rate of progression of children and young adults with SCD and albuminuria over time. PROCEDURE: Urine albumin/creatinine (A/C) ratios and serum creatinine were obtained serially. Serum cystatin C levels were determined in a subgroup of 20 patients. RESULTS: Of 38 patients with SCD who had albuminuria (30 with microalbuminuria and 8 with proteinuria), 10.5% had progressive disease during follow-up of 20 +/- 12 months. Progressive disease was observed in 2 of 30 patients with MA because MA worsened to either intermittent proteinuria (1 patient), or persistent proteinuria after 7 months follow-up (1 patient). Two of eight patients with proteinuria worsened to nephrotic-range after 8 and 17 months with elevations of serum creatinine. All eight patients with proteinuria were treated with angiotensin blockade and/or hydroxyurea. Of those, six patients responded to treatment with decreased albuminuria and no changes in serum creatinine. Serum cystatin C level trended to increase before serum creatinine in patients with proteinuria. CONCLUSIONS:Patients with rapid progression to nephrotic-range proteinuria showed decreased kidney function. Therefore, patients with albuminuria should be monitored closely for progression, and therapy with hydroxyurea and/or angiotensin blockade should be considered for patients who develop proteinuria. Serum cystatin C appears more sensitive than serum creatinine to detect early decrease in kidney function. (c) 2007 Wiley-Liss, Inc.
Authors: Lauren J Becton; Ram V Kalpatthi; Elizabeth Rackoff; Deborah Disco; John K Orak; Sherron M Jackson; Ibrahim F Shatat Journal: Pediatr Nephrol Date: 2010-05-27 Impact factor: 3.714
Authors: Malgorzata Kasztan; Brandon M Fox; Jeffrey D Lebensburger; Kelly A Hyndman; Joshua S Speed; Jennifer S Pollock; David M Pollock Journal: Blood Adv Date: 2019-05-14
Authors: Russell E Ware; Renee C Rees; Sharada A Sarnaik; Rathi V Iyer; Ofelia A Alvarez; James F Casella; Barry L Shulkin; Eglal Shalaby-Rana; C Frederic Strife; John H Miller; Peter A Lane; Winfred C Wang; Scott T Miller Journal: J Pediatr Date: 2010-01 Impact factor: 4.406
Authors: Marianne McPherson Yee; Shameem F Jabbar; Ifeyinwa Osunkwo; Lisa Clement; Peter A Lane; James R Eckman; Antonio Guasch Journal: Clin J Am Soc Nephrol Date: 2011-09-22 Impact factor: 8.237
Authors: Rima S Zahr; Marianne E Yee; Jack Weaver; Katherine Twombley; Raed Bou Matar; Diego Aviles; Rajasree Sreedharan; Michelle N Rheault; Rossana Malatesta-Muncher; Hillarey Stone; Tarak Srivastava; Gaurav Kapur; Poornima Baddi; Oded Volovelsky; Jonathan Pelletier; Rasheed Gbadegesin; Wacharee Seeherunvong; Hiren P Patel; Larry A Greenbaum Journal: Pediatr Nephrol Date: 2019-04-03 Impact factor: 3.714
Authors: Banu Aygun; Nicole A Mortier; Matthew P Smeltzer; Jane S Hankins; Russell E Ware Journal: Pediatr Nephrol Date: 2011-05-11 Impact factor: 3.714
Authors: Santosh L Saraf; Xu Zhang; Tamir Kanias; James P Lash; Robert E Molokie; Bharvi Oza; Catherine Lai; Julie H Rowe; Michel Gowhari; Johara Hassan; Joseph Desimone; Roberto F Machado; Mark T Gladwin; Jane A Little; Victor R Gordeuk Journal: Br J Haematol Date: 2013-12-12 Impact factor: 6.998
Authors: Omar Niss; Adam Lane; Monika R Asnani; Marianne E Yee; Ashok Raj; Susan Creary; Courtney Fitzhugh; Prasad Bodas; Santosh L Saraf; Sharada Sarnaik; Prasad Devarajan; Punam Malik Journal: Blood Adv Date: 2020-04-14
Authors: Geraldo B Silva Junior; Ana Patrícia F Vieira; Amanda X Couto Bem; Marília P Alves; Gdayllon C Meneses; Alice M C Martins; Sonia M H A Araújo; Alexandre V Libório; Elizabeth F Daher Journal: Int J Clin Pharm Date: 2014-06-17